PharmaBlock Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
April 28, 2022 at 04:13 pm IST
Share
PharmaBlock Sciences (Nanjing), Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 1,201.27 million compared to CNY 1,022.1 million a year ago. Revenue was CNY 1,201.63 million compared to CNY 1,022.23 million a year ago. Net income was CNY 486.56 million compared to CNY 184.21 million a year ago. Basic earnings per share from continuing operations was CNY 2.46 compared to CNY 0.99 a year ago. Diluted earnings per share from continuing operations was CNY 2.44 compared to CNY 0.98 a year ago.
PharmaBlock Sciences Nanjing Inc is a company mainly engaged in design, synthesis and sales of pharmaceutical molecular building blocks. The Company's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The Company is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.